Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 9:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,022 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Severe Behavior Disorder Clear all

Conditions: Anxiety, Depression - Major Depressive Disorder, Stress
Interventions: Mobile health application; Behavioral
Lead sponsor: Texas A&M University; Other
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: College Station, Texas

Conditions: Major Depressive Disorder
Interventions: Agomelatine (AGO178C), Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 582 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 47
States / cities: Birmingham, Alabama • Beverly Hills, California • Encino, California + 41 more

Conditions: Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
Interventions: SPT-300, Placebo; Drug
Lead sponsor: Seaport Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 29
States / cities: Chino, California • Garden Grove, California • Glendale, California + 25 more

Conditions: Major Depressive Disorder
Interventions: Ixekizumab; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 70 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe, Criminal Behavior
Interventions: BNI Chatbot, OUD Education & Treatment Resources; Behavioral
Lead sponsor: Center for Progressive Recovery, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Major Depressive Disorder
Interventions: Computer Task Manipulation; Behavioral
Lead sponsor: Mclean Hospital; Other
Eligibility: 14 Years to 18 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Major Depressive Disorder
Interventions: AXS-05, Bupropion; Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Beverly Hills, California • Jacksonville, Florida • Orlando, Florida + 1 more

Conditions: Major Depressive Disorder
Interventions: Rest, Aerobic Activity; Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Attention Deficit Disorder With Hyperactivity
Interventions: Methylphenidate HCl, Risperidone, Parent Management Training (PMT), Placebo; Drug · Behavioral
Lead sponsor: Michael Aman; Other
Eligibility: 6 Years to 12 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 4
States / cities: Stony Brook, New York • Cleveland, Ohio • Columbus, Ohio + 1 more

Conditions: Trisomy 13 Syndrome, Arthrogryposis Congenita Multiplex With Intestinal Atresia, Asparagine Synthetase Deficiency, CHARGE Syndrome, Early Infantile Epileptic Encephalopathy, FOXG1 Syndrome, KBG Syndrome, Noonan Syndrome, Severe Hemophilia A, Short Bowel Syndrome, Beta-Propeller Protein-Associated Neurodegeneration, Brain Injury of Prematurity With Periventricular Leukomalacia, Chromosome 17p13.3 Microdeletion Syndrome, Chromosome 1q43-1q44 Deletion, Cockayne Syndrome, Congenital Diaphragmatic Hernia, End-Stage Renal Disease With Cloacal Anomaly, Mitochondrial Depletion Disorder, Severe Factor VII Deficiency
Interventions: Family Centered pediatric palliative care for family caregivers of children with rare diseases.; Behavioral
Lead sponsor: Children's National Research Institute; Other
Eligibility: 12 Months to 99 Years
Enrollment: 480 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Depression
Interventions: Sertraline, Placebo, BupropionXL; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 296 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 4
States / cities: Boston, Massachusetts • Ann Arbor, Michigan • New York, New York + 1 more

Conditions: Depression
Interventions: Guided Mindfulness Practice using a study created web app that links to the commercially available Waking Up app; Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Charleston, South Carolina

Conditions: Depressive Disorder
Interventions: SSR149415; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Major Depressive Disorder
Interventions: (2R,6R)-Hydroxynorketamine hydrochloride, Placebo; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Major Depressive Disorder
Interventions: Placebo, NBI-1065845; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 17
States / cities: Birmingham, Alabama • Huntsville, Alabama • Riverside, California + 14 more

Conditions: Depression
Interventions: Escitalopram; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Major Depression, Healthy Participants
Interventions: Sham iTBS, TMS, D-cycloserine, Dextromethophan, Placebo; Device · Drug
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Major Depressive Disorder
Interventions: Internet Cognitive Behavioral Therapy; Behavioral
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 45 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Major Depressive Disorder
Interventions: Not listed
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 55 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Spinal Cord Injury, Depression - Major Depressive Disorder, Veteran
Interventions: Psilocybin (Usona Institute); Drug
Lead sponsor: James J. Peters Veterans Affairs Medical Center; Federal
Eligibility: 22 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Bipolar Depression, Suicidal Ideas, Suicidal Ideation, Suicide, Attempted
Interventions: NRX-101 Oral Capsule, Lurasidone Oral Capsule, Ketamine Intravenous Infusion, Saline Solution Intravenous Infusion; Drug
Lead sponsor: NeuroRx, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Birmingham, Alabama • Fort Lauderdale, Florida • Charlotte, North Carolina + 1 more

Conditions: Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms, Cardiovascular Diseases, Heart Diseases, Coronary Artery Disease, Stroke
Interventions: Beating the Blues (BtB), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications, Usual Care; Behavioral · Drug · Other
Lead sponsor: Indiana University; Other
Eligibility: 50 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Depressive Disorder, Major, Major Depressive Disorder (MDD)
Interventions: Bupropion Hydrochloride Extended-release, Extended-release Venlafaxine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 347 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 45
States / cities: Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 40 more

Conditions: Depression, Major Depressive Disorder
Interventions: Intermittent theta burst stimulation, Sham theta burst stimulation, Continuous theta burst stimulation; Device
Lead sponsor: Marta Peciña, MD PhD; Other
Eligibility: 18 Years to 55 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

An Interactive Mobile Health (mHealth) App as Intervention for High Anxiety and Depression in College Students

Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder

A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)

Targeting IL-17A for Treatment-Resistant Depression

A Brief Negotiation Interview Chatbot to Improve Buprenorphine Engagement Among Justice-Involved Individuals

Neural Correlates of Stress and Perceived Control in Adolescent Depression

Assessing Symptomatic Clinical Episodes in Depression

Exercise-priming of CBT for Depression: the CBT+ Trial

Treatment of Severe Childhood Aggression (The TOSCA Study)

Palliative Care Needs of Children With Rare Diseases and Their Families

Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression

Mindfulness Training During Accelerated TMS for Depression

An Eight-Week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Major Depressive Disorder

Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine

Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD)

Brain Energy Metabolism in Individuals With Major Depressive Disorder Receiving Escitalopram

Synaptic Mechanisms of Intermittent Theta Burst Stimulation for Major Depressive Disorder

Internet Based Cognitive Behavioral Therapy Effects on Depressive Cognitions and Brain Function

Neuronal Responses to Social Feedback in Major Depressive Disorder

Psilocybin to Treat Depression in Spinal Cord Injury

Sequential Therapy for the Treatment of Severe Bipolar Depression.

eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients

Sexual Functioning Study With Antidepressants

Rapid Antidepressant Dynamics in Acute Neuromodulation Treatments